Although activation or overexpression of ERβ has been shown to reduce cell proliferation in several cancers, including those of the breast, ovary, prostate, and colon [12,13,30,31], the therapeutic significance of ERβ in GBM remains elusive. Here, ESR2 is linked to cancer.